Trends in complexity of single-agent and combination therapies for solid tumor cancers approved by the US Food and Drug Administration
Given that clinical benefit appears limited in combination therapy compared with monotherapy, drug development could focus on simplifying cancer therapies toward patient-centered paradigms.
Authors
- Rajat Thawani (ORCID: https://orcid.org/0000-0002-5378-9434)
- Akshit Chitkara (ORCID: https://orcid.org/0000-0003-0198-186X)
- Julia Hamilton (ORCID: https://orcid.org/0000-0003-2935-8826)
- Emerson Y. Chen (ORCID: https://orcid.org/0000-0003-3035-4478)
- P Manoj (ORCID: https://orcid.org/0000-0003-4162-033X)
- Preeyam Roy
- Yash Tadikonda
- Dakota W Nollner
Institutions
- University of California, Riverside (US)
- Oregon Health & Science University (US)
- University of Chicago (US)
- Saint Louis University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1093/oncolo/oyae302
- Citations
- 5
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 5.65
Funders
- Knight Cancer Institute, Oregon Health and Science University